N4 Pharma PLC on Tuesday said its business outreach is ongoing as it continued to work on getting Nuvec, its delivery system for vaccines and cancer treatment, into clinic.

The Derby, England-based pharmaceutical company said pretax loss in the first half of 2023 narrowed 14% to £646,150 from £750,102 a year prior. It does not yet generate revenue.

Chair Chris Britten said that the quickest way to get Nuvec into clinic ‘may be to do this ourselves in a step-by-step manner.’

‘We are considering how we might formulate an small interfering RNA product for a combination therapy using multiple loaded siRNA, thereby utilising the direct competitive advantages Nuvec has ourselves. We are also looking at the prospect of using our oral delivery work for a potential inflammatory bowel disease product and we will also continue our acquisition search for new opportunities that might enable us to get into clinic as soon as possible,’ he said.

In July, N4 Pharma had said that the University of Queensland, from which N4 Pharma has licenced the exclusive rights to Nuvec, said it has been informed that a further patent application for Nuvec in the US has been granted.

The patent is for the composition of matter of the nanoparticle itself. It sits alongside the first US patent grant announced last January, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the company.

N4 Pharma shares were flat at 1.40 pence per share on Tuesday afternoon in London.

Copyright 2023 Alliance News Ltd. All Rights Reserved.